Stifel upgraded Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) to Buy from Hold, with a price target of $20 from $14, after reevaluating the competitive landscape for the 2L GIST market.
Every savvy investor understands that relying solely on a stock’s past performance is not a reliable predictor of future gains. It has become a well-known adage, a cliché taught in Econ 101: “Past performance does not guarantee future returns.” However, while this statement holds true, it raises an important question: How should investors evaluate a stock? In reality, the past serves as a prologue, not a prophet, and investors can capitalize on considering past performance among other factors wh
Operator: Good day, everyone and welcome to Affimed s First Quarter 2023 Earnings and Corporate Update Call. At this time, all participants are in a listen-only mode.
Stifel Starts Theseus Pharmaceuticals Inc. (THRX) at Buy streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.